{"created":"2021-03-01T06:27:51.366688+00:00","id":22677,"links":{},"metadata":{"_buckets":{"deposit":"74b7d266-5234-465e-b7e1-3b783007f6d1"},"_deposit":{"id":"22677","owners":[],"pid":{"revision_id":0,"type":"depid","value":"22677"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00022677","sets":["453:456","471:537:538:1203"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"The Thrapeutic Model of Systemic Lupus Erythematosus(Autoimmune Diseases)"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1989-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageEnd":"982","bibliographicPageStart":"977","bibliographicVolumeNumber":"103","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The therapeutic effect of 15－deoxyspergualin (DSP), a newly developed immunosuppressive agent, on the development of spontaneously occuring lupus glomerulonephritis in MRL/1pr and male BXSB mice was examined. Administration of the drug was begun from the age of 13 weeks, when polyclonal B cell activation and lupus nephropathy were apparent. Treatment with DSP up to 20 weeks of age at a dose of 2mg/kg twice a day, 5mg/kg daily or 20mg/kg three times a week strongly suppressed the increment of IgG-producing cell numbers in the spleen, and decreased serum levels of immune complexes and anti-DNA antibodies. Glomerular histological score by light microscopy and IgG and C3 deposition estimated by immunofluorescence were remarkably improved. In MRL/1pr mice, DSP reduced the swelling of lymph node and the numbers of Thy-1^+, B220^+ cell population in lymphoid organs. Responsiveness to Con A and IL-2 production of spleen cells were improved by the treatment. Thus, DSP was shown to suppress the progression of polyclonal B cell activation and lupus nephropathy in MRL/1pr and male BXSB mice. These results suggest that DSP might be used as a therapeutic agent for human erythematosus.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"137505","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Ito, Satoshi"}]},{"nameIdentifiers":[{"nameIdentifier":"137506","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Fujiwara, Michio"}]},{"nameIdentifiers":[{"nameIdentifier":"137507","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Arakawa, Masaaki"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊藤, 聡"}],"nameIdentifiers":[{"nameIdentifier":"137502","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"藤原, 道夫"}],"nameIdentifiers":[{"nameIdentifier":"137503","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"荒川, 正昭"}],"nameIdentifiers":[{"nameIdentifier":"137504","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-19"}],"displaytype":"detail","filename":"103(12)_977-982.pdf","filesize":[{"value":"2.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"103(12)_977-982.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/22677/files/103(12)_977-982.pdf"},"version_id":"b161f1f5-bd68-4704-b151-f927e1dbdf83"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Murine Lupus","subitem_subject_scheme":"Other"},{"subitem_subject":"MRL/1pr mice","subitem_subject_scheme":"Other"},{"subitem_subject":"Male BXSB mice","subitem_subject_scheme":"Other"},{"subitem_subject":"Polyclonal B cell activation","subitem_subject_scheme":"Other"},{"subitem_subject":"Immunosuppressant","subitem_subject_scheme":"Other"},{"subitem_subject":"ループスモデルマウス","subitem_subject_scheme":"Other"},{"subitem_subject":"MRL/1prマウス","subitem_subject_scheme":"Other"},{"subitem_subject":"BXSB雄マウス","subitem_subject_scheme":"Other"},{"subitem_subject":"多クローン性B細胞活性化","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫抑制剤","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)"},{"subitem_title":"4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1203"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-04-13"},"publish_date":"2016-04-13","publish_status":"0","recid":"22677","relation_version_is_last":true,"title":["4) エリテマトーデスの治療モデル(シンポジウム 自己免疫疾患, 第445回新潟医学会)"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:53:01.411157+00:00"}